authors with a view to stimulating debate amongst the readers.
Other data are generally low volume. Grabenwoger treated 21 patients with a 100% technical success rate and two deaths (9.5%). 9 Won and colleagues managed 23 patients with aneurysmal disease. 10 All 11 patients Aneurysms with degenerative aneurysms were treated successfully whereas there were two failures from 12 The published 30-day mortality following surgical re-patients with chronic dissections. There were no deaths pair of aneurysmal disease of the descending thoracic or paraplegia within 30 days and 91% survival at 1 aorta is in the region of 2-21% with the majority of year. A series from Japan details 15 patients with units reporting 5-15%. [1] [2] [3] [4] However a recent audit of chronic dissections who were successfully treated cardiothoracic units in Great Britain and Ireland without death or paraplegia. No death or rupture showed a 34% mortality rate for procedures performed occurred out to an average follow-up of 24 months. 11 on bypass and 25% when performed without bypass. 5 Whilst these data support the use of stent-grafts there Other complications of thoracic surgery include para-are a number of problems. Firstly the volume of data plegia or paraparesis in up to 5%, particularly where remains small with a lack of information on longsurgery extends beyond the 8th intercostal space, renal term outcomes. Secondly, the relative costs of the two failure in 5%, stroke in 3%, cardiac and pulmonary therapies is unknown. Thirdly, we are all aware of the problems in 10% and 28% of patients. 4, 6 Postoperative structural failure of abdominal stent-grafts. The data recovery is often protracted with time spent on an for thoracic work is smaller volume with shorter folintensive care unit, and long-term rehabilitation may low-up. However one major provider of thoracic stentbe considerable. Understandably the potential benefits grafts has already voluntarily removed their device of a "minimally invasive" treatment utilising stent-from the market because of stent and spine fractures. graft technology are attractive. Most data arises from In order for patients to appreciate the short-term gain the U.S.A. The reported mortality rate is 0-9% with a from the stent-graft compared to surgery, the devices paraplegia and stroke rate of less than 3%, and an must be robust enough to show longevity. Finally, in incidence of renal insufficiency around 4% using com-order to provide Grade A recommendations the curmercially available devices. 7 The hospital stay has been rent guidelines require at least one randomised conreduced to an average of 3 days. Using first generation trolled trial.
12 Herein lies the crux of the problem. Given the marked disparity in 30 day outcomes be- * Please address all correspondence to: P. A. Gaines, Consultant tween surgery and treatment with stent-grafts it is Vascular Radiologist, Sheffield Vascular Institute, Northern General difficult to conceive how clinicians can retain equipoise Hospital, Sheffield S5 7AU, U.K.
that would enable them to randomise patients between policy makers may be reluctant to sanction the use of thrombosis of the false lumen was achieved in 74% of cases, partial thrombosis in the rest and an associated stent-grafts. This problem has recently been overcome in the U.K. with the insight and understanding of the reduction in the size of aorta and false lumen over time with no late deaths due to aortic rupture. Czermak Safety and Efficacy Register of New Interventional Procedures of the Medical Royal Colleges (SERNIP). has also treated six of seven patients (seven acute, two chronic) successfully. 23 The perception of the difference Whilst this group has recommended that thoracic stent-grafts should only be placed as part of primary in outcomes between surgery and stent-graft therapy for complicated type B dissection has lead to a number research (category C) they have recently agreed that submission of data to a National Thoracic Stent-Graft of approaches. Some clinicians now feel that stentgrafts should be considered the treatment of choice. Registry fulfils this criteria. Hopefully other regulatory authorities will follow suite.
This largely ignores the small volume of available data and lack of long-term outcome measures. Perhaps for them submission of data to a large registry should be mandatory. Others see the need for a randomised Trauma controlled trial (RCT). Unfortunately no funded study is currently available.
Traumatic thoracic aortic transections are an attractive
Even more controversial is the use of stent-grafts to situation in which to consider stent grafts. Only 14-18% manage uncomplicated acute type B dissections. The of patients with this type of injury reach hospital number of patients not offered surgery or stent-graft alive and approximately 15-39% will die during or who die late or require subsequent intervention for following surgery. Approximately 2.3-28% of patients late dissection related events that may be remedied by will develop paraplegia, the higher rate being as-stent-graft induced thrombosis of the false lumen (i.e. sociated with the "clamp and sew" technique rather late rupture, aneurysm formation, progression of ischthan the use of bypass or Gott Shunt. 13 Excellent results aemia or dissection) is difficult to estimate from the from endovascular repair have been reported, with literature but is probably approximately 12-30%. 20, 24, 25 0-17% mortality and no paraplegia in four small It has been demonstrated that false lumen patency series.
14-17 Whilst these data are small, and the long-following dissection predicts both long term aneurysm term integrity of stent-grafts in patients, some of whom formation and death, 26 and that stent-grafts induce will be young, is unknown, the potential for a min-false lumen thrombosis. 22 If the supposition that false imally invasive treatment to treat these extremely sick lumen thrombosis stops late events is correct then patients seems clear. More widespread application of stent-grafts may be able to stop delayed rupture of this technique will require the instant availability of the aorta following type B dissection. However with no stent-grafts and the dissemination of this expertise to active intervention the false lumen will spontaneously all major trauma centres. thrombose in 50% of patients 5 years following type B dissection, and there are of course cost implications to a therapy that may only benefit 12-30% of patients in the long-term. 26 Currently health purchasers are Acute Dissection unlikely to agree to the treatment of uncomplicated type B and a RCT is required. The majority of acute type B dissections are now managed medically with surgery being reserved for complications (rupture, refractory hypertension, localised false aneurysms, continued pain or branch vesTerminology sel ischaemia) which results in a 30 day operative mortality of 31-64%. [18] [19] [20] [21] If an abdominal operation is The assessment of the value of value of stent-grafts in chronic dissections is confused by nomenclature. To required then there is an 80% operative mortality.
18
Stent-grafts have been used primarily to manage acute many surgeons the clinical picture of chronic dissection is a patient who presents with a thoracic aortic anbranch vessel ischaemia complicating type B dissection. The largest series from Stanford demonstrated eurysm where imaging demonstrates a dissection that occurred many years ago. However chronicity is often relief of ischaemia in 76% of cases; all cases of dynamic obstruction and 40% of cases where the obstruction is used to describe a dissection of more than 2 weeks old and, using this definition, two recent publication thought to be a combination of dynamic and static obstruction. 22 The early 30-day mortality rate was only has advocated stent grafts for chronic dissection.
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Clearly there is a huge difference in the potential for 16%. Of importance was the observation that complete 
